Lead Product(s): ‘1805
Therapeutic Area: Immunology Product Name: IRL201805
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Revolo Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 09, 2021
Under the terms of the agreement, Northway will provide the full scope of its’ services ranging from cell line development to batch production of ‘1805 Active Pharmaceutical Ingredients (API) and drug product, following Current Good Manufacturing Practices (cGMP).